Acurx Pharmaceuticals, Inc. (ACXP)
NASDAQ (CM) NASDAQ (CM) Primary 
XMUN Summary
Axos Aims to Expand AI-Powered Financial Services With Arc Acquisition
Axos Financial subsidiary Axos Nevada Holding plans to acquire Arc Technologies to expand Axos' artificial intelligence capabilities and enhance its ability to serve small businesses across the United States.
Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's Why
Acurx Pharmaceuticals (ACXP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Acurx Pharmaceuticals, Inc. (ACXP) Q1 2026 Earnings Call Transcript
Acurx Pharmaceuticals, Inc. (ACXP) Q1 2026 Earnings Call Transcript
Acurx Pharmaceuticals, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Hui Fai Tam Caitong International Asset Management Co. Ltd. | 23 | $36 | $32.89 | -$3.11 | -8.64% |
 Sean Rooney Prospect Financial Services LLC | 13,785 | $59,140.38 | $20,126.1 | -$39,014.28 | -65.97% |
Acurx Pharmaceuticals, Inc. (ACXP) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Acurx Pharmaceuticals, Inc. ever had a stock split?
Acurx Pharmaceuticals, Inc. Profile
| Biotechnology Industry | Healthcare Sector | David Luci CEO | NASDAQ (CM) Exchange | 00510M203 CUSIP |
| US Country | 4 Employees | - Last Dividend | 5 Aug 2025 Last Split | - IPO Date |
Overview
Acurx Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company with a focused mission to develop antibiotics for treating bacterial infections. Since its incorporation in 2017, the company has positioned itself at the forefront of battling antibiotic resistance by engineering novel therapeutic agents. This endeavor addresses the urgent need for new treatments against resilient bacterial strains that traditional antibiotics can no longer combat effectively. Operating from its headquarters in Staten Island, New York, Acurx Pharmaceuticals leverages groundbreaking research and clinical expertise to advance its mission.
Products and Services
-
Ibezapolstat:
This is Acurx Pharmaceuticals' flagship antibiotic candidate, which exhibits a novel mechanism of action by targeting the polymerase IIIC enzyme. Currently in Phase 2b clinical trial, ibezapolstat is being developed to treat patients with Clostridium difficile infections—a serious and potentially life-threatening condition. The uniqueness of ibezapolstat lies in its innovative approach to combating bacterial infections, representing a significant advance in the field of antibiotics.
-
ACX-375C:
ACX-375C is in the pipeline as a potential treatment for infections caused by gram-positive bacteria. This includes formidable pathogens such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals is developing ACX-375C to be administrable both orally and parenterally, indicating its versatility and broad application potential in combatting resistant bacterial infections.
